RRM2 and neoplasm: Importantly, patients whose PAC simultaneously expressed CCNF, RRM2, and SPDL1 at high level had dramatically shorter survival time compared to those patients whose tumor tissue expressed all these markers at low level (250 days vs. 1502 days; p < 0.0001; Figure 3G; HR = 4.64, 95% CI 2.61–8.27; Table 5), or those patients whose PACs expressed only one of these markers at high level (p = 0.04).